Skip to main content

Table 3 Characteristics of patients with diabetes according to concomitant events

From: Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes

 

3. Diabetes w/o event

4. Diabetes with event

NHIS

NHIS + Eze

HIS

HIS + Eze

p value*

NHIS

NHIS + Eze

HIS

HIS + Eze

p value*

Nr. patients n (%)

5661 (85)

447 (7)

532 (8)

33 (1)

 

2057 (54)

325 (9)

1289 (34)

115 (3)

 

Adherent n (%)

4777 (84)

404 (90)

461 (87)

33 (100)

< 0.001

1677 (82)

294 (91)

1085 (84)

106 (92)

< 0.001

Total-chol (mg/dl)a

154.2 (34)

153.7 (37)

149.8 (37)

155.3 (48)

N.S

138.8 (37)

136.9 (34)

130.5 (35)

136.6 (44)

< 0.001

LDL-chol (mg/dl)a

81.7 (27)

79.6 (30)

79.2 (29)

87.5 (39)

N.S

73.1 (28)

68.8 (27)

67.6 (27)

72.1 (36)

< 0.001

HDL-chol (mg/dl)a

49.5 (15)

48.7 (14)

46.4 (14)

43 (9)

< 0.001

42.6 (14)

43.7 (14)

41.1 (13)

41.5 (12)

< 0.01

Triglycerides (mg/dl)a

108.9 (70)

122.5 (79)

114.3 (74)

109.2 (65)

< 0.001

100.7 (68)

106.6 (71)

97.6 (71)

96 (61)

N.S

NON-HDL-chol (mg/dl)a

104.7 (32)

105 (35)

103.4 (34)

112.3 (48)

N.S

96.2 (34)

93.2 (31)

89.4 (33)

95.1 (43)

< 0.001

GFR (ml/min/1.73 m2)a

94.7 (33)

92.5 (31)

93.8 (32)

98.7 (29)

N.S

75.2 (37)

71.8 (37)

82 (36)

86.5 (40)

< 0.001

HbA1c (mmol/mol)a

55.7 (13)

56.4 (13)

55.8 (13)

56 (15)

N.S

55.1 (14)

54.4 (14)

56.2 (15)

56.9 (14)

N.S

CHD

     

920 (45)

175 (54)

619 (48)

72 (63)

< 0.001

Cerebrovascular disease

     

790 (38)

86 (27)

531 (41)

28 (24)

< 0.001

PAD

     

8 (0)

N.I

N.I

0 (0)

N.S

ACEi/ARB

3986 (70)

320 (72)

395 (74)

26 (79)

N.S

1502 (73)

243 (75)

1000 (78)

91 (79)

< 0.05

Beta blockers

1588 (28)

152 (34)

213 (40)

16 (49)

< 0.001

1116 (54)

221 (68)

816 (63)

91 (79)

< 0.001

CCB

1669 (30)

127 (28)

147 (28)

7 (21)

N.S

742 (36)

119 (37)

491 (38)

43 (37)

N.S

Fibrates

64 (1)

12 (3)

14 (3)

0 (0)

< 0.01

22 (1)

5 (2)

15 (1)

N.I

N.S

Insulin

1366 (24)

136 (30)

154 (29)

9 (27)

< 0.01

823 (40)

144 (44)

498 (39)

49 (43)

N.S

Metformin

3724 (66)

258 (58)

333 (63)

25 (76)

< 0.01

906 (44)

132 (41)

643 (50)

59 (51)

 = 0.001

Sulfonylureas

1131 (20)

88 (20)

100 (19)

N.I

N.S

290 (14)

39 (12)

174 (14)

11 (10)

N.S

DPP-4

300 (5)

36 (8)

25 (5)

N.I

N.S

171 (8)

29 (9)

89 (7)

7 (6)

N.S

GLP-1

160 (3)

17 (4)

17 (3)

N.I

N.S

29 (1)

8 (3)

26 (2)

5 (4)

N.S

SLGT2

69 (1)

12 (3)

11 (2)

0 (0)

< 0.05

24 (1)

6 (2)

17 (1)

6 (5)

< 0.01

  1. Opinion 05/2014 on “Anonymisation Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving less than three patients were not reported, as potentially reconductable to single individuals. Therefore, results referred to ≤ 3 patients were reported as NI (not issuable)
  2. CHD coronary heart disease, PAD peripheral artery disease, ACEi angiotensin converting-enzyme inhibitors, ARBs angiotensin II receptor blocker, CCB calcium channel blockers
  3. *ANOVA P value for differences between groups (i.e., if < 0.05 not all group are equivalent)
  4. aAnalyses performed on patients with at least one detection before index
Back to article page